Furthers Baxter’s continued innovation in medication delivery and management Integrates Baxter’s decades of leadership in infusion therapy with innovative digital health solutions to build on the ...
In the second quarter, Baxter turned in 1% operational sales growth and 28% adjusted EPS growth. Also, management reduced its guidance for 2025, including operational sales growth of 3% to 4% (down ...
Baxter’s efforts this summer to correct high-risk issues with its infusion pumps has gotten more complicated. Last month, the company and the FDA alerted the public to a problem with the large-volume ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results